{
Vertex Pharmaceuticals Inc

Companies

}
CRISPR Therapeutics gains momentum with Medicaid plan for gene-editing treatment
CRISPR Therapeutics has faced a 23% decline in stock value this year despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The high cost of $2.2 million per treatment poses accessibility challenges, but a new U.S. government plan aims to help Medicaid patients afford it, potentially expanding access for many. However, the company reported only $1.6 million in revenue in the first nine months, indicating slow uptake of Casgevy.
Yahoo Finance
United States Dollar Vertex Pharmaceuticals Inc CRISPR Therapeutics AG SAU BHR GBR USA Joe Biden Show more
Healthcare, Market Report
18:25 22.12.2024
CRISPR Therapeutics gains momentum with new Medicaid plan for gene therapy access
CRISPR Therapeutics has faced a challenging market, with shares down 23% year-to-date despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The Biden administration's new Medicaid initiative aims to improve access to Casgevy, potentially expanding its market significantly. With a projected peak annual sales exceeding $2.2 billion, the company is well-positioned for future growth, although it currently reports minimal revenue.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc bluebird bio, Inc. CRISPR Therapeutics AG SAU USA BHR GBR Show more
Healthcare, Market Report
18:25 22.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for expedited development and potential early revenue generation, enhancing the company's financial flexibility. The off-the-shelf manufacturing approach of CTX112 could lead to more consistent patient responses, positioning CRISPR favorably for future growth despite inherent clinical trial risks.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc CRISPR Therapeutics AG CHE
Healthcare, Market Report
15:30 20.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for a potentially expedited approval process, offering financial flexibility and a simpler manufacturing approach. While the new development is promising, the success of CTX112 still hinges on convincing safety and efficacy data in clinical trials.
@AOL
Vertex Pharmaceuticals Inc Apple Inc. NVIDIA Corporation Netflix, Inc. CRISPR Therapeutics AG USA Alex Carchidi Show more
Healthcare, Market Report
15:30 20.12.2024
merck shifts focus to biotech and obesity as keytruda exclusivity looms
Merck & Co. is shifting its focus from TIGIT and LAG-3 inhibitors to a subcutaneous version of Keytruda and a PD-1x/VEGF bispecific, while entering the obesity market with a preclinical GLP-1 receptor agonist from Hansoh Pharma for $112 million. Sanofi reported promising mid-stage results for its TL1A antibody duvakitug in inflammatory bowel disease, achieving significant remission rates, while Vertex Pharmaceuticals faced setbacks with its NaV1.8 inhibitor suzetrigine in chronic pain trials. Novo Nordisk completed a $16.5 billion acquisition of Catalent to address supply issues for semaglutide, despite ongoing shortages, while Novartis announced the closure of two MorphoSys sites, affecting 330 employees, following an $800 million write-down on pelabresib.
firstwordpharma.com
United States Dollar Sanofi Vertex Pharmaceuticals Inc Merck & Co., Inc. Catalent, Inc. Novartis AG Novo Nordisk A/S USA Show more
Healthcare, Market Report
04:47 20.12.2024
dow jones attempts recovery as micron plunges and nvidia rebounds
The Dow Jones Industrial Average attempted to recover from a significant 1,100-point drop, gaining 0.4% after a 2.6% decline. Micron's shares plummeted 17% following disappointing earnings guidance, while Nvidia rebounded 2.4% after five days of losses. Economic indicators showed a surprising 3.1% GDP growth and lower jobless claims, but market volatility persisted.
Investor's Business Daily
United States Dollar Vertex Pharmaceuticals Inc Tesla, Inc. NVIDIA Corporation Lennar Corp Micron Technology, Inc. Darden Restaurants, Inc. USA Kimberley Koenig Show more
Finance & Economy, Market Report
16:34 19.12.2024
stock market faces sharp sell-off as yields rise and major stocks tumble
The stock market faced significant losses following the Federal Reserve's rate outlook, with the Dow Jones plunging 2.6% and the S&P 500 down 2.95%. Major tech stocks like Nvidia and Tesla also fell, while Micron's weak guidance led to a sharp decline in its shares. Despite a slight bounce in futures, the market remains volatile, with rising Treasury yields and economic uncertainty ahead.
Investor's Business Daily
United States Dollar Vertex Pharmaceuticals Inc Bank of England WESTERN DIGITAL Micron Technology, Inc. Applied Materials, Inc. Tesla, Inc. NVIDIA Corporation SEAGATE TECHNOLOGY HOLDINGS Taiwan Semiconductor Co., Ltd. Bank of Japan USA Donald Trump Elon Musk Jerome Powell Show more
Finance & Economy, Market Report
14:16 19.12.2024
vertex pharmaceuticals stock outperforms market amid mixed sector performance
Vertex Pharmaceuticals (VRTX) closed at $468.09, up 0.94%, outperforming the S&P 500's 0.38% gain. Despite a 0.42% decline over the past month, analysts anticipate a revenue increase to $2.77 billion for the upcoming earnings report, although EPS is projected to drop by 3.1%. Currently, VRTX holds a Zacks Rank of #3 (Hold) with a high Forward P/E ratio of 934.65, indicating a premium valuation compared to its industry.
Yahoo Finance
Vertex Pharmaceuticals Inc USA
Healthcare, Market Report
23:50 16.12.2024
crisper therapeutics faces challenges despite first mover advantage in gene therapy
CRISPR Therapeutics, a pioneer in gene therapy, faces challenges despite its first FDA-approved CRISPR-based therapy, Casgevy. With shares down 46% from their peak and minimal revenue reported, the company must navigate intense competition and financial losses while aiming for future growth. Investors are advised to proceed with caution until sales momentum is evident.
Barchart.com
United States Dollar Intellia Therapeutics, Inc. Beam Therapeutics Inc. CRISPR Therapeutics AG Vertex Pharmaceuticals Inc CHE Dan Victor Show more
Healthcare, Market Report
16:32 14.12.2024
CRISPR Therapeutics faces challenges despite FDA approval of groundbreaking therapy
CRISPR Therapeutics, a leader in gene therapy, achieved a milestone with the FDA's approval of its Casgevy product for sickle cell disease, marking the first CRISPR-based therapy. Despite a promising pipeline and $1.9 billion in cash, the company faces challenges with slow commercialization and minimal revenue from Casgevy, which has only reached one patient so far. As it prepares for expanded indications and updated efficacy data by 2025, investors remain cautious amid a 46% drop in share value from its 52-week high.
Yahoo Finance
Vertex Pharmaceuticals Inc CRISPR Therapeutics AG USA
Healthcare, Market Report
15:45 14.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.